• BridgeBio Pharma highlighted new Phase 3 ATTRibute-CM analyses on acoramidis for transthyretin amyloid cardiomyopathy at Heart Failure 2026, with results already presented in late-breaking sessions.
• Data reinforced a disease-modifying profile, showing more stable biomarker response over time versus placebo, which the analyses linked to better survival outcomes.
• Separate results showed earlier separation on outpatient worsening heart failure versus placebo, supporting a faster clinical impact than typically seen with disease-modifying therapy in ATTR-CM.
• An indirect comparison versus Pfizer’s tafamidis suggested fewer cardiovascular hospitalizations with acoramidis, with a favorable mortality trend, which could strengthen competitive positioning in a market led by tafamidis.
• Acoramidis is marketed as Attruby in US, with the company flagging additional data presentations for future medical meetings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110930PRIMZONEFULLFEED9716800) on May 11, 2026, and is solely responsible for the information contained therein.